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Available online 9 February 2016Background:We analyzed the literature to assess the coincidental impact on migraines of transcatheter patent
foramen ovale (PFO) closure performed for secondary stroke prevention.
Methods:We searchedMedline, EMBASE, and the Cochrane database for studies published up until August 2013.
We included English-language studies that provided information on complete resolution or improvement in
migraine headaches following PFO closure. Two study authors identiﬁed 375 original articles and both indepen-
dently reviewed 32 relevant manuscripts. Data including study methodology, inclusion criteria, PFO closure and
migraine outcomeswere extractedmanually from all eligible studies. Pooled odds (and probability) of resolution
or improvement of migraine headaches were calculated using random-effects models.
Results: Twenty studies were analyzed. Most were uncontrolled studies that included a small number of patients
with cryptogenic stroke who had undergone PFO closure and had variable time of follow-up. The probability of
complete resolution of migraine with PFO closure (18 studies, 917 patients) was 0.46 (95% conﬁdence interval
0.39, 0.53) and of any improvement in migraine (17 studies, 881 patients) was 0.78 (0.74, 0.82). There was
evidence for publication bias in studies reporting on improvement in migraines (Begg's p = 0.002), but not for
studies on complete resolution of migraine (p = 0.3). In patients with aura, the probability of complete resolu-
tion of migraine post-PFO closure was 0.54 (0.43, 0.65), and in those without aura, complete resolution occurred
in 0.39 (0.29, 0.51).
Conclusions: Among patients with unexplained stroke and migraine undergoing transcatheter PFO closure,
resolution of headaches occurred in amajority of patientswith aura and for a smaller proportion of patientswith-
out aura.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Migraine1. Introduction
Migraine is a primary headache disorder. Twelve percent of the adult
U.S. general population have migraines, of which 30% have associated
aura [1,2]. A foramen ovale is an embryological inter-atrial shunt that
remains patent in up to 25% of the general adult population based on
autopsy evaluation [3]. Patent foramen ovale (PFO) has been noted in
40% to 60% of migraineurs [4], especially in those with preceding aura
[5–7]. In addition, migraineurs have been known to have intracardiacramen ovale; RCT, randomized
r Diseases and Department of
irst Street SW, Rochester, MN
irvatham).
. This is an open access article underright-to-left shuntingmore commonly [5]. A PFO provides the potential
for shunting portal and systemic venous metabolites like serotonin to
the cerebral blood ﬂow, bypassing their removal during pulmonary
circulation passage. Serotonin can lead to platelet activation and aggre-
gation in the cerebral circulation and is thought to be the initiating
trigger of migraines in susceptible individuals [8]. Similar to PFO, the
creation of an ASD with transseptal puncture for catheter ablation of
atrial ﬁbrillation has been suggested to be associated with migraine
headaches that resolve over time, presumably as the ASD closes [9].
The results of available studies involving PFO and migraine, and the
inﬂuence of PFO closure on resolution of migraine symptoms are
variable. In a population-based cohort study, PFO detected with
transthoracic echocardiography and agitated saline was not associated
with self-reported migraine [10]. The MIST trial (Migraine Intervention
With STARFlex Technology) was a negative randomized sham-
controlled study on PFO closure for drug refractory migraines [11].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Studies included in the meta-analysis.
No. Author Year Design Patient subset Migraine assessment Follow-up
(months)
Antiplatelet drugs
1. Wilmshurst [26] 2000 Uncontrolled Decompression illness
Paradoxical embolism
Large ASD
Questionnaire for frequency,
duration, and intensity of migraine
episodes
9–30 m Aspirin 6 m
2. Morandi [27] 2003 Uncontrolled Cryptogenic stroke Questionnaire for frequency,
duration, and intensity of migraine
episodes
12 Aspirin 6 m
3. Post [28] 2004 Uncontrolled Paradoxical embolism
Systemic desaturation
Questionnaire for frequency,
duration, and intensity of migraine
episodes
6 Low dose aspirin (duration not
mentioned)
4. Schwerzmann [29] 2004 Uncontrolled Paradoxical embolism Neurologist classiﬁed the headache 12 Clopidogrel 1 m
Aspirin 6 m
5. Azarbal [30] 2005 Uncontrolled Cryptogenic stroke MIDAS 12 Clopidogrel 3 m
Aspirin indeﬁnitely
6. Mortelmans [18] 2005 Uncontrolled ASD Questionnaire for frequency,
duration, and intensity of migraine
episodes
29 –
7. Reisman [31] 2005 Uncontrolled Paradoxical cerebral embolism Standardized migraine questionnaire 12 Clopidogrel 3 m
Aspirin 6 m
8. Anzola [32] 2006 Case–control Stroke MSS 12 Aspirin 300 mg
9. Giardini [13] 2006 Uncontrolled Stroke/TIA MIDAS 12 Aspirin 12 m
Ticlopidine 3 m
Warfarin 6 m with thrombophilia
10. Slavin [33] 2007 Uncontrolled Cryptogenic stroke
TIA
Desaturation
MIDAS
Frequency and severity assessed
30 –
11. Dubiel [34] 2008 Uncontrolled Paradoxical embolism Questionnaire for frequency,
duration, and intensity of migraine
episodes
38 Aspirin 6 m
12. Jesurum [35] 2008 Uncontrolled Paradoxical cerebral embolism Questionnaire for frequency,
duration, and intensity of migraine
episodes
24 Clopidogrel 3 m
Aspirin ≥6 m
13. Luermans [36] 2008 Uncontrolled Paradoxical embolism Questionnaire for frequency,
duration, and intensity of migraine
episodes
6 Clopidogrel 1 m
Aspirin ≥6 m
14. Chessa [37] 2009 Uncontrolled TIA
Ischemic lesions on CT/MRI
Severe migraine
MSS 6 Aspirin + Clopidogrel 1 m
Aspirin 5 m
15. Kimmelstiel [38] 2009 Case–control Stroke/paradoxical embolism MIDAS 3 Clopidogrel 6 m
Aspirin indeﬁnitely
16. Vigna [39] 2009 Case–control Subclinical brain MRI lesions Questionnaire for frequency,
duration, and intensity of migraine
episodes
16 Clopidogrel 3 m
Aspirin 6 m
17. Wahl [40] 2010 Uncontrolled Paradoxical embolism Questionnaire for frequency,
duration, and intensity of migraine
episodes
60 Clopidogrel 1–6 m
Aspirin 6 m
18. Trabattoni [41] 2011 Uncontrolled Embolic CVA MSS 28 Aspirin 6 m
19. Rigatelli [42] 2012 Uncontrolled High risk for paradoxical embolism MIDAS 18 –
20. Nagpal [43] 2013 Uncontrolled Cryptogenic stroke (93%)
Peripheral embolism
Hypoxemia
Intractable migraine
Frequency and severity on a 0–10
scale
55.2 Aspirin (duration not mentioned)
Clopidogrel (duration not
mentioned)
Warfarin (8%)
ASD, atrial septal defect; CT, computerized tomography; CVA, cerebrovascular accident; MIDAS, migraine disability assessment test; MRI, magnetic resonance imaging;MSS, migraine se-
verity score; TIA, transient ischemic attack.
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lence of PFO, and themigraine frequencywas reducedwith PFO closure
as compared to migraineurs without preceding aura [12]. Partial or
complete relief of migraine symptoms has been reported with trans-
catheter PFO closure performed for secondary stroke prevention or
prevention of decompression illness [13]. However, most studies have
not elucidated the distinction between partial and complete relief from
migraines with transcatheter closure of PFO. The difference between mi-
graine with and without aura in patients undergoing PFO device-based
closure has not been well deﬁned. The pathogenesis of migraine with
auramay differ from that without aura, and this difference may have im-
plications on the effect of PFO closure on migraine outcome.
Given the discrepant results among studies and the limited sample
sizes of someof these studies,we performed ameta-analysis to evaluate
the effect of PFO closure on resolution or improvement of migraine. Our
objective was to conduct a systematic review of relevant existing litera-
ture to examine the effect of PFO closure on themigraine symptoms andto identify a subgroup, if any, which could beneﬁt more from PFO
closure.
2. Methods
2.1. Search strategy
Following theMeta-analysis of Observational Studies in Epidemiolo-
gy (MOOSE) guidelines [14], we conducted a comprehensive literature
search of studies published in Medline, EMBASE, and the Cochrane
Library databases for studies published until August 2013. Keywords
used were migraine, migraineurs, migraine headaches, patent foramen
ovale or PFO, closure of PFO, heart septal defect, atrial septal defect, atri-
al septal aneurysm, percutaneous or surgical or operative procedure,
transient ischemic attack, stroke, and atrial ﬁbrillation.
Studies that met each of the following criteria were considered
eligible for the meta-analysis: 1) published in English, and 2) studies
Fig. 1. Study ﬂow diagram.
9S.M. Kanwar et al. / Clinical Trials and Regulatory Science in Cardiology 15 (2016) 7–13reporting a formal assessment of migraine before PFO closure and at
follow-up. We did not exclude studies without a control arm if they
reported frequency and severity of migraine before and after the PFO
closure. Studies thatwere not subjected to a formal peer-reviewprocess
were excluded from the meta-analysis. The title and abstract of all arti-
cles meeting the search criteria were reviewed by two of the study
authors (S.K., A.N.). Full reports of 32 potentially relevant articles were
then independently reviewed by these two authors to establish eligibil-
ity based on the deﬁned inclusion criteria.
2.2. Data extraction
A standardized, piloted data extraction form was used for recording
information. Data extraction was completed by one of the authors (SK),Table 2
Pooled estimates (odds and probability) of resolution or any improvement of migraines follow
Outcome Studies # Patients # Odds [95% CI]
Complete resolution of migraine
Overall population 18 917 0.85 [0.64, 1.14
Patients with migraine with aura 13 427 1.17 [0.74, 1.84
Patients with migraine without aura 12 206 0.64 [0.40, 1.04
Improvement of migraine (partial/complete resolution)
Overall population 17 881 3.63 [2.80, 4.71
Patients with migraine with aura 13 499 4.40 [3.22, 6.01
Patients with migraine without aura 12 211 2.47 [1.37, 4.46
CI, conﬁdence interval.
⁎ Begg's test for publication bias.and veriﬁed by a second author (AN). Study populations with migraine
were characterized by the presence or absence of aura, and the
following information was recorded: study design (observational or
randomized; controlled or uncontrolled), primary author, publication
year, indication for PFO closure, follow-up duration, number and
duration of antiplatelet therapy, number of participants, resolution or
improvement (deﬁned as ≥50% improvement in migraine headaches).
Disagreement between reviewers during the selection process was
resolved through consensus.
The quality of the studieswas assessed on the basis of elements from
the Strengthening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) checklist for observational studies [15].We did not assign
a threshold for study inclusion. Inconsistencies among studies were
found in determination of bias, selection of participants in the study,
determination of study size, handling of quantitative variables, and
determination of the source of funding.
Each study contributed only one effect size per analysis. If data were
duplicated between studies, themost recent studywas used. If frequen-
cieswere not given, theywere estimated frompercentages and rounded
to the nearest integer. If any cell had a zero count, odds were calculated
by adding 0.5 to avoid division by zero.2.3. Statistical analyses
For the twoprimary analyses,wepooled the log odds of 1) resolution
of migraine and 2) improvement (partial/complete resolution) in
migraine using random-effects models, with corresponding 95% conﬁ-
dence intervals (CI). Pooled odds were converted to pooled probability
of outcome. The I2 statistic (percentage of variance in the pooled
estimate due to inter-study variance) was used to examine the hetero-
geneity of effect sizes in the overall aggregations: I2 ≤ 25% indicated low
heterogeneity and I2 ≥ 75% indicated high heterogeneity.
Publication bias was evaluated using a Begg's funnel plot, and
statistical testing for publication bias performed was assessed using
Begg's and Egger's methods with p b 0.05 suggesting evidence for the
presence of publication bias [16,17]. Statistical analyseswere performed
using Review Manager (RevMan) Version 5.3 (Copenhagen, The
CochraneCollaboration, 2014) andwww.wessa.net. Two-tailed p values
less than 0.05 were considered statistically signiﬁcant.3. Results
We identiﬁed 375 articles from our deﬁned search strategy. After
review of the abstracts, we identiﬁed 32 potentially relevant studies
and these manuscripts were reviewed in detail. We then excluded 12
studies that did not report relevant data or were duplicate reports.
Twenty studies were thus included in the pooled analyses (Table 1,
Fig. 1). PFO closure was performed in all but one study for secondary
prevention of stroke or other embolic events, and in one study for
closure of a hemodynamically signiﬁcant atrial septal defect [18].ing PFO closure.
Probability [95% CI] Heterogeneity I2 (%) Publication bias (p-value)⁎
] 0.46 [0.39, 0.53] 76 0.3
] 0.54 [0.43, 0.65] 77 0.4
] 0.39 [0.29, 0.51] 54 0.3
] 0.78 [0.74, 0.82] 54 0.002
] 0.81 [0.76, 0.86] 37 0.06
] 0.71 [0.58, 0.82] 64 0.06
Fig. 2.Metaanalysis: (A) complete and (B) partial/complete resolution of migraine headaches following PFO closure.
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The pooled result for resolution of migraine was derived from 18
studies comprising 917 patients undergoing PFO closure. The pooled
odds of resolution of migraine at follow-up were 0.85 (95% CI 0.64,
1.14), translating to a pooled probability of resolution of 0.46 (0.39,
0.53). There was a large heterogeneity between study results (I2 =
76%). Improvement in migraine (partial/complete resolution) was
obtained from 17 studies involving 881 patients. Odds of improvement
were 3.63 (2.80, 4.71) or probability 0.78 (0.74, 0.82), with moderate
heterogeneity (I2 = 54%) (Table 2, Fig. 2).
3.2. Publication bias
Both Begg's and Egger's tests suggested no apparent publication
bias for the outcome of resolution of migraine (p = 0.26 and 0.21
respectively). However, there was asymmetry in results for theimprovement in migraine outcome with smaller studies suggesting
a larger beneﬁt (Begg's p = 0.002; Egger's p = 0.004) (Table 2,
Fig. 3).
3.3. Migraine with aura
Following PFO closure among the subgroup of migraineurs with
aura, the pooled probability of resolution of migraine was 0.54 (0.43,
0.65), and the pooled probability for any improvement was 0.81 (0.76,
0.86) (Table 2, Fig. 4A).
3.4. Migraine without aura
For patients without aura, the pooled probability of resolution ofmi-
graine with PFO closure was 0.39 (0.29, 0.51) and pooled probability of
improvement was 0.71 (0.58, 0.82) (Table 2, Fig. 4B).
Fig. 3. Begg's publication bias plots: (A) complete resolution, (B) partial/complete resolution of migraine with PFO closure.
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We found in studies primarily evaluating transcatheter closure of
PFO for secondary prevention of stroke, that 46% (95% CI 39%, 53%) of
patients with migraines had a resolution of their symptoms. There
was a large heterogeneity in the results reported from different studies.
The numerical proportion of patients with resolution of migraines was
more for those with aura 54% (43%, 65%) compared to those without
aura 39% (29%, 51%). The assessment of any improvement in migraine
headaches (78% [74%, 82%] patients) had moderate heterogeneity, and
suggested evidence for publication bias.
Pathophysiological attributes linking right-to-left shunting across
PFO and migraine include microemboli and chemicals like serotonin
which bypass clearance/metabolism that is thought to occur
within the pulmonary circulation [8,19]. Migraineurs with aurahave a higher prevalence of PFO than migraineurs without aura and
non-migraineurs [20]. In our meta-analysis, we found that this sub-
group had higher rates of migraine improvement and resolution
after PFO closure.
There have been two randomized controlled trials (RCTs) for PFO
closure as treatment for migraines with aura refractory to multiple
drugs —MIST [11] and PRIMA [21]. Both studies were negative for the
primary efﬁcacy endpoint. We did not include the results of these
RCTs in our analysis because PRIMA has not yet been published and
MIST did not report the results on the proportions of patients with vary-
ing degrees of beneﬁt. MIST showed that at 6 months, PFO closure was
not statistically different from a sham procedure in eliminating head-
ache, headache frequency, or migraine disability scores; though there
was a suggestion of reduction in headache days. PRIMA has not yet
been published, but results show a non-statistically signiﬁcant
Fig. 4.Migraine with aura: (A) complete and (B) partial/complete resolution of migraine with aura with PFO closure Migraine without aura: (C) complete and (D) partial/complete
resolution of migraine without aura with PFO closure.
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ical therapy. However, a signiﬁcant reduction in migraine with aura
days was seen at 1 year, with a mean reduction of migraines with aura
days of −2.4 (PFO closure group) versus −0.6 (medical therapy
group) days/month from a baseline of 4.1 and 4.0 days/month, respec-
tively. Limitations of these RCTs include small sample size, inclusion of
patients with chronic headache, operator learning curve in PFO closure,
procedural complications, and short follow-up periods.
The patients included in these RCTswere being treated primarily for
refractorymigraines, and thus are inherently different from those in our
meta-analysis which almost only included patients with stroke and
associated migraine. It is possible that there is a relationship between
migraine and stroke and beneﬁt of PFO closure as seen commonly in
this subgroup, especially if they present with aura. A meta-analysis of
14 studies demonstrated 2-fold increased association between mi-
graines and ischemic stroke, especially in patients with aura (relative
risk 2.27) [22]. It is also known thatmigraineurswith stroke have higher
prevalence of PFO (84%) as compared to migraineurs without a neuro-
logical event (38%) [23]. It is, therefore, conceivable that there is a rela-
tionship between cerebrovascular events andmigraines in the presence
of PFO and it is this subset that may beneﬁt from PFO closure.
Irrespectively, our results are not necessarily contradictory to the nega-
tive RCTs andmight reﬂect the absence of a control group. This is exem-
pliﬁed by the PFO closure group in PRIMA where 40% became free of
migrainewith aura. The placebo effect inmigraineurs is known to inﬂu-
ence their improvement in symptoms and that response may be
exaggerated with PFO closure [24,25]. Recollection bias may have also
inﬂuenced the results of uncontrolled studies.
There was a large heterogeneity in reported results from the includ-
ed studies. This variability could be due to the differences in patient
population, differences in techniques, methodology and quality of
migraine assessment, bias in recall and reporting, differences in fol-
low-up and other factors. Most studies in our analysis had a sample
size of less than 100. The type and duration of anticoagulation therapy
following PFO closure were disparate with many studies relying on
aspirin monotherapy but others using dual antiplatelet therapy with
clopidogrel or ticlopidine, and occasional use of oral anticoagulation.
PFOs were detected during evaluation for cryptogenic stroke and inﬂu-
ence of PFO closure on frequency and severity of migrainewas detected
using different scoring systems, thus making inter-study comparisons
difﬁcult. We also noted some evidence of publication bias in assessment
of any beneﬁt, and it is possible that studies reporting negligible beneﬁt
did not get published andwere unavailable to be included in our pooled
estimates.In conclusion, the collective evidence in patients with migraine
undergoing PFO closure for other indications (mostly secondary stroke
prevention) suggests that a majority of those with aura have resolution
of their headache symptoms. Small RCTs of PFO closure for drug-
refractory migraine with aura have failed to show statistical beneﬁt
from PFO closure. Whether this discordance is because of placebo effect
in uncontrolled studies, recollection or publication bias, or beneﬁt
restricted to migraines in setting of thromboembolic neurological
events needs to be teased out with well-designed prospective studies.
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